|
2024-02-26 |
2024-02-08 |
A
Achat
|
Schneid Yair
Large shareholder
|
150 000
+1.9%
0,17
25 650
USD
|
150 000
+1.9%
|
0,17
|
25 650
USD
|
|
|
2024-02-26 |
2024-02-07 |
A
Achat
|
Schneid Yair
Large shareholder
|
150 000
+1.9%
0,17
25 935
USD
|
150 000
+1.9%
|
0,17
|
25 935
USD
|
|
|
2024-02-26 |
2024-02-07 |
A
Achat
|
Schneid Yair
Large shareholder
|
25 000
+0.3%
0,17
4 250
USD
|
25 000
+0.3%
|
0,17
|
4 250
USD
|
|
|
2024-02-26 |
2024-02-06 |
A
Achat
|
Schneid Yair
Large shareholder
|
25 000
+0.3%
0,20
5 025
USD
|
25 000
+0.3%
|
0,20
|
5 025
USD
|
|
|
2024-02-26 |
2024-02-05 |
A
Achat
|
Schneid Yair
Large shareholder
|
97 402
+1.3%
0,18
17 922
USD
|
97 402
+1.3%
|
0,18
|
17 922
USD
|
|
|
2024-02-26 |
2024-01-30 |
A
Achat
|
Schneid Yair
Large shareholder
|
335 000
+4.6%
0,18
60 635
USD
|
335 000
+4.6%
|
0,18
|
60 635
USD
|
|
|
2024-02-26 |
2024-01-29 |
A
Achat
|
Schneid Yair
Large shareholder
|
150 000
+2.1%
0,18
27 000
USD
|
150 000
+2.1%
|
0,18
|
27 000
USD
|
|
|
2023-03-20 |
2023-03-16 |
A
Achat
|
Bachleda Mark
Chief Commercial Officer
Dirigeant
|
11 000
+inf%
2,25
24 717
USD
|
11 000
+inf%
|
2,25
|
24 717
USD
|
|
|
2023-03-14 |
2023-03-13 |
A
Achat
|
Degnan Chris
Chief Financial Officer
Dirigeant
|
10 000
+inf%
1,96
19 593
USD
|
10 000
+inf%
|
1,96
|
19 593
USD
|
|
|
2023-03-14 |
2023-03-10 |
A
Achat
|
Sorensen Mel
President and CEO
Administrateur exécutif
|
100 000
+43.1%
1,68
168 120
USD
|
100 000
+43.1%
|
1,68
|
168 120
USD
|
|
|
2021-12-20 |
2021-12-17 |
A
Achat
|
West Linda
Administrateur non-exécutif
|
20 000
+50.0%
2,74
54 804
USD
|
20 000
+50.0%
|
2,74
|
54 804
USD
|
|
|
2021-09-03 |
2021-09-01 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
47 756
-100.0%
8,47
404 498
USD
|
47 756
-100.0%
|
8,47
|
404 498
USD
|
|
|
2021-06-17 |
2021-06-15 |
A
Achat
|
West Linda
Administrateur non-exécutif
|
10 000
+33.3%
9,13
91 300
USD
|
10 000
+33.3%
|
9,13
|
91 300
USD
|
|
|
2021-06-04 |
2021-06-02 |
A
Achat
|
West Linda
Administrateur non-exécutif
|
10 000
+50.0%
8,65
86 511
USD
|
10 000
+50.0%
|
8,65
|
86 511
USD
|
|
|
2021-06-03 |
2021-06-01 |
A
Achat
|
Alleva Lawrence M
Administrateur non-exécutif
|
4 045
+inf%
8,59
34 741
USD
|
4 045
+inf%
|
8,59
|
34 741
USD
|
|
|
2021-06-02 |
2021-06-01 |
A
Achat
|
West Linda
Administrateur non-exécutif
|
10 000
+100.0%
8,64
86 381
USD
|
10 000
+100.0%
|
8,64
|
86 381
USD
|
|
|
2021-06-02 |
2021-05-28 |
A
Achat
|
West Linda
Administrateur non-exécutif
|
10 000
+inf%
8,64
86 410
USD
|
10 000
+inf%
|
8,64
|
86 410
USD
|
|
|
2021-02-19 |
2021-02-18 |
V
Vente
|
Novo Holdings A/S
Large shareholder
|
500 000
-16.9%
10,58
5 290 000
USD
|
500 000
-16.9%
|
10,58
|
5 290 000
USD
|
|
|
2020-11-17 |
2020-11-13 |
A
Achat
|
Alleva Lawrence M
Administrateur non-exécutif
|
2 325
+58.1%
10,22
23 771
USD
|
2 325
+58.1%
|
10,22
|
23 771
USD
|
|
|
2020-11-16 |
2020-11-13 |
V
Vente
|
Sussman Joel F.
Chief Accounting Officer
Dirigeant
|
10 000
-100.0%
10,32
103 197
USD
|
10 000
-100.0%
|
10,32
|
103 197
USD
|
|
|
2020-11-16 |
2020-11-12 |
V
Vente
|
Sussman Joel F.
Chief Accounting Officer
Dirigeant
|
10 000
-100.0%
10,06
100 627
USD
|
10 000
-100.0%
|
10,06
|
100 627
USD
|
|
|
2020-10-28 |
2020-10-26 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
2 244
-100.0%
15,00
33 660
USD
|
2 244
-100.0%
|
15,00
|
33 660
USD
|
|
|
2020-10-19 |
2020-10-15 |
V
Vente
|
Novo Holdings A/S
Large shareholder
|
450 000
-13.2%
11,00
4 950 000
USD
|
450 000
-13.2%
|
11,00
|
4 950 000
USD
|
|
|
2020-10-07 |
2020-10-06 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
10 536
-100.0%
12,00
126 432
USD
|
10 536
-100.0%
|
12,00
|
126 432
USD
|
|
|
2020-10-07 |
2020-10-05 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
100
-100.0%
12,00
1 200
USD
|
100
-100.0%
|
12,00
|
1 200
USD
|
|
|
2020-06-22 |
2020-06-19 |
V
Vente
|
Novartis Bioventures Ltd
Former 10% Owner
|
1 001 312
-28.9%
8,25
8 260 824
USD
|
1 001 312
-28.9%
|
8,25
|
8 260 824
USD
|
|
|
2020-06-22 |
2020-06-18 |
V
Vente
|
Novartis Bioventures Ltd
Former 10% Owner
|
900
-0.0%
9,04
8 136
USD
|
900
-0.0%
|
9,04
|
8 136
USD
|
|
|
2020-06-17 |
2020-06-17 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
4 622
-0.1%
9,27
42 846
USD
|
4 622
-0.1%
|
9,27
|
42 846
USD
|
|
|
2020-06-17 |
2020-06-16 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
8 600
-0.2%
9,30
79 980
USD
|
8 600
-0.2%
|
9,30
|
79 980
USD
|
|
|
2020-06-17 |
2020-06-15 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
6 164
-0.2%
9,05
55 784
USD
|
6 164
-0.2%
|
9,05
|
55 784
USD
|
|
|
2020-06-12 |
2020-06-12 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
1 500
-0.0%
9,19
13 785
USD
|
1 500
-0.0%
|
9,19
|
13 785
USD
|
|
|
2020-06-12 |
2020-06-11 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
7 200
-0.2%
9,21
66 312
USD
|
7 200
-0.2%
|
9,21
|
66 312
USD
|
|
|
2020-06-12 |
2020-06-10 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
8 532
-0.2%
9,46
80 713
USD
|
8 532
-0.2%
|
9,46
|
80 713
USD
|
|
|
2020-06-09 |
2020-06-09 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
7 000
-0.2%
9,38
65 660
USD
|
7 000
-0.2%
|
9,38
|
65 660
USD
|
|
|
2020-06-09 |
2020-06-08 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
5 659
-0.2%
9,66
54 666
USD
|
5 659
-0.2%
|
9,66
|
54 666
USD
|
|
|
2020-06-09 |
2020-06-05 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
8 652
-0.2%
9,66
83 578
USD
|
8 652
-0.2%
|
9,66
|
83 578
USD
|
|
|
2020-06-04 |
2020-06-04 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
4 088
-0.1%
9,55
39 040
USD
|
4 088
-0.1%
|
9,55
|
39 040
USD
|
|
|
2020-06-04 |
2020-06-03 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
5 208
-0.1%
9,78
50 934
USD
|
5 208
-0.1%
|
9,78
|
50 934
USD
|
|
|
2020-06-04 |
2020-06-02 |
V
Vente
|
Novartis Bioventures Ltd
Large shareholder
|
5 669
-0.2%
9,68
54 876
USD
|
5 669
-0.2%
|
9,68
|
54 876
USD
|
|
|
2020-05-28 |
2020-05-26 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
692
-100.0%
12,00
8 304
USD
|
692
-100.0%
|
12,00
|
8 304
USD
|
|
|
2020-05-22 |
2020-05-21 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
1 174
-100.0%
12,00
14 088
USD
|
1 174
-100.0%
|
12,00
|
14 088
USD
|
|
|
2020-05-22 |
2020-05-20 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
969
-100.0%
12,00
11 628
USD
|
969
-100.0%
|
12,00
|
11 628
USD
|
|
|
2020-05-12 |
2020-05-12 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
671
-100.0%
12,00
8 052
USD
|
671
-100.0%
|
12,00
|
8 052
USD
|
|
|
2020-05-12 |
2020-05-11 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
185
-100.0%
12,00
2 220
USD
|
185
-100.0%
|
12,00
|
2 220
USD
|
|
|
2020-05-12 |
2020-05-08 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
5 102
-100.0%
12,00
61 224
USD
|
5 102
-100.0%
|
12,00
|
61 224
USD
|
|
|
2020-05-07 |
2020-05-07 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
2 059
-100.0%
12,00
24 709
USD
|
2 059
-100.0%
|
12,00
|
24 709
USD
|
|
|
2020-05-07 |
2020-05-06 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
1 489
-100.0%
12,00
17 868
USD
|
1 489
-100.0%
|
12,00
|
17 868
USD
|
|
|
2020-05-07 |
2020-05-05 |
VP
Vente planifiée
|
HOLMLUND JON T
Chief Medical Officer
Dirigeant
|
3 064
-100.0%
12,16
37 258
USD
|
3 064
-100.0%
|
12,16
|
37 258
USD
|
|
|
2019-12-17 |
2019-12-13 |
A
Achat
|
Alleva Lawrence M
Administrateur non-exécutif
|
4 000
+inf%
9,78
39 139
USD
|
4 000
+inf%
|
9,78
|
39 139
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Clarus IV-A, L.P.
Large shareholder
|
19 423
+17.5%
12,00
233 076
USD
|
19 423
+17.5%
|
12,00
|
233 076
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Clarus IV-A, L.P.
Large shareholder
|
97 131
+17.5%
12,00
1 165 572
USD
|
97 131
+17.5%
|
12,00
|
1 165 572
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Clarus IV-A, L.P.
Large shareholder
|
52 660
+17.5%
12,00
631 920
USD
|
52 660
+17.5%
|
12,00
|
631 920
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Clarus IV-A, L.P.
Large shareholder
|
80 786
+17.5%
12,00
969 432
USD
|
80 786
+17.5%
|
12,00
|
969 432
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Novo Holdings A/S
SEE REMARKS
Large shareholder
|
500 000
+17.2%
12,00
6 000 000
USD
|
500 000
+17.2%
|
12,00
|
6 000 000
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Blackstone Clarus GP L.P.
Large shareholder
|
19 423
+17.5%
12,00
233 076
USD
|
19 423
+17.5%
|
12,00
|
233 076
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Blackstone Clarus GP L.P.
Large shareholder
|
97 131
+17.5%
12,00
1 165 572
USD
|
97 131
+17.5%
|
12,00
|
1 165 572
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Blackstone Clarus GP L.P.
Large shareholder
|
52 660
+17.5%
12,00
631 920
USD
|
52 660
+17.5%
|
12,00
|
631 920
USD
|
|
|
2019-11-14 |
2019-11-12 |
A
Achat
|
Blackstone Clarus GP L.P.
Large shareholder
|
80 786
+17.5%
12,00
969 432
USD
|
80 786
+17.5%
|
12,00
|
969 432
USD
|
|
|
2019-11-12 |
2019-11-12 |
A
Achat
|
Sofinnova Venture Partners IX, L.P.
Large shareholder
|
750 000
+32.1%
12,00
9 000 000
USD
|
750 000
+32.1%
|
12,00
|
9 000 000
USD
|
|
|
2019-11-12 |
2019-11-12 |
A
Achat
|
New Enterprise Associates 14, L.P.
Large shareholder
|
416 666
+10.6%
12,00
4 999 992
USD
|
416 666
+10.6%
|
12,00
|
4 999 992
USD
|
|
|
2019-11-12 |
2019-11-12 |
A
Achat
|
Novartis Bioventures Ltd
Large shareholder
|
250 000
+7.6%
12,00
3 000 000
USD
|
250 000
+7.6%
|
12,00
|
3 000 000
USD
|
|
